The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABVC | +110.59% | -96.95% | -50.22% | -94% |
| S&P | +17.45% | +75.43% | +11.88% | +480% |
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$214.04K | -20.7% |
| Gross Margin | -9020.85% | 0.0% |
| Market Cap | $51.76M | 576.1% |
| Market Cap / Employee | $2.72M | 0.0% |
| Employees | 19 | 0.0% |
| Net Income | -$3,016.46K | -2439.4% |
| EBITDA | -$1,984.87K | -1181.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.33M | 53.6% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.60M | 576.0% |
| Short Term Debt | $1.98M | -33.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.30% | -11.7% |
| Return On Invested Capital | -248.40% | -106.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$593.38K | -139.8% |
| Operating Free Cash Flow | -$587.58K | -137.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.61 | 6.33 | 8.47 | 4.27 | 376.23% |
| Price to Sales | 16.06 | 31.21 | 98.88 | 35961.36 | 216144.38% |
| Price to Tangible Book Value | 1.61 | 6.33 | 8.47 | 4.27 | 376.24% |
| Enterprise Value to EBITDA | -17.19 | -9.30 | -22.66 | -37.71 | -41.63% |
| Return on Equity | -27.0% | -39.9% | -48.1% | -128.2% | 31.60% |
| Total Debt | $2.99M | $2.31M | $2.63M | $3.58M | 11.70% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
